Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 102 Parkinson's papers of 3,070 | 0.39 |
| pathways Reactome | 3 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 3155
Sealed predictions
- MFN2 in dopamine neurons, braak+0.11 (p 0.787) → -0.19 (p 0.631)receipt 3163
In the sealed studies
- Mitochondrial quality control and Lewy stage: did not hold
Swarm cases
receipt 3163: MFN2 in dopamine neurons, braak
- power
- full sample +0.00 (p 0.997, n 18), 95% CI -0.47 to +0.47. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.00 (p 0.997, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.08 (p 0.754, n 18). could be the mix.
- skeptic
- leave-one-out range -0.09 to +0.13, sign flips 12; without severely affected donors +0.00 (p 0.997, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MFN2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts